News Marinus Pharmaceuticals, Inc.

Equities

MRNS

US56854Q2003

Real-time Estimate Cboe BZX Other stock markets 12:28:50 2024-05-08 pm EDT			5-day change	1st Jan Change
1.545 ^USD	-1.59%		+5.78%	-85.69%

02:57pm	Earnings Flash (MRNS) MARINUS PHARMACEUTICALS Reports Q1 Revenue $7.7M, vs. Street Est of $9.1M	MT
01:00pm	Marinus Pharmaceuticals, Inc. Increases Earnings Guidance for Full Year 2024	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (MRNS) MARINUS PHARMACEUTICALS Reports Q1 Revenue $7.7M, vs. Street Est of $9.1M	08:57am	MT
Marinus Pharmaceuticals: Q1 Earnings Snapshot	07:30am	AQ
Marinus Pharmaceuticals : Corporate Overview Slide Deck	07:17am	PU
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results	07:01am	BU
Marinus Pharmaceuticals, Inc. Increases Earnings Guidance for Full Year 2024	07:00am	CI
HC Wainwright Adjusts Price Target on Marinus Pharmaceuticals to $11 From $27, Maintains Buy Rating	May. 07	MT
Marinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare Conference	May. 02	BU
Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024	May. 01	BU
Truist Adjusts Marinus Pharmaceuticals' PT to $10 From $25, Keeps Buy Rating	Apr. 17	MT
Baird Downgrades Marinus Pharmaceuticals to Neutral, Price Target at $2	Apr. 16	MT
RBC Downgrades Marinus Pharmaceuticals to Sector Perform From Outperform, Slashes Price Target to $3 From $24, Keeps Speculative Risk	Apr. 16	MT
North American Morning Briefing : Powell Comments, -2-	Apr. 16	DJ
Sector Update: Health Care Stocks Softer Late Afternoon	Apr. 15	MT
Marinus Pharmaceuticals Shares Fall After Phase 3 Trial Interim Analysis of Ganaxolone	Apr. 15	MT
Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results	Apr. 15	BU
Marinus Pharmaceuticals, Inc. Provides Update on the Phase 3 RAISE Trial	Apr. 15	CI
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)	Apr. 05	BU
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus Post Grant Review	Mar. 28	AQ
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review	Mar. 27	BU
Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) added to S&P Pharmaceuticals Select Industry Index	Mar. 17	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Marinus Pharmaceuticals, Inc.

Equities

MRNS

US56854Q2003

Summary

Filters